HIV (Human Immunodeficiency Virus) Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about HIV (Human Immunodeficiency Virus) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Not Applicable

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

HIV (Human Immunodeficiency Virus)
University of California, San Francisco33 enrolled1 locationNCT07115901
Recruiting
Not Applicable

Improving Access to HIV Testing for Children in Uganda

HIV (Human Immunodeficiency Virus)
University of California, San Francisco400 enrolled1 locationNCT07236905
Recruiting
Phase 2

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

Metabolic SyndromeObesity, OverweightHIV (Human Immunodeficiency Virus)
Abdelrahman Mahmoud66 enrolled1 locationNCT07336797
Recruiting

Questioning the Epidemiology of Asymptomatic TB

TuberculosisHIV (Human Immunodeficiency Virus)HIV+1 more
Barcelona Institute for Global Health6,770 enrolled1 locationNCT07312266
Recruiting
Phase 1

The DART DELIVER-02 Study

HIV (Human Immunodeficiency Virus)
University of North Carolina, Chapel Hill24 enrolled3 locationsNCT07217379
Recruiting
Not Applicable

Integrating Project YES! With WHO-Endorsed Mental Health Approaches Among Youth Living With HIV

AnxietyHIV (Human Immunodeficiency Virus)Mental Health+2 more
Johns Hopkins Bloomberg School of Public Health400 enrolled1 locationNCT07221201
Recruiting
Phase 4

HIV Prevention With PrEP Among People on Opioid Replacement Therapy

HIV (Human Immunodeficiency Virus)
Cara Spence350 enrolled6 locationsNCT07160075
Recruiting
Phase 3

DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

ObesityHIV (Human Immunodeficiency Virus)Overweight and/or Obesity
José Antonio Mata Marín306 enrolled1 locationNCT07075146
Recruiting
Not Applicable

Pre-exposure Prophylaxis (PrEP) for Health

HIV (Human Immunodeficiency Virus)Substance Dependence
Brown University200 enrolled2 locationsNCT04430257